Management of antiphospholipid syndrome

Papa, Nicoletta Del; Vaso, N.

doi:10.1177/1759720x10365969

Cited by 11 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Refractory APS, whether primary or secondary and catastrophic APS could be the appropriate targets for these therapies currently [61]. …”

Section: Managementmentioning

confidence: 99%

“…Moreover, treatment SLE-APS patients with HSCT and rituximab appears to be promising also, but further investigation and more clinical trials are required to evaluate the safety profile of these drugs, to identify the patients suitable for these aggressive therapeutic approaches and to know the effect of these approaches as long term cures of APS. Refractory APS, whether primary or secondary and catastrophic APS could be the appropriate targets for these therapies currently [ 61 ].…”

Section: Managementmentioning

confidence: 99%

See 1 more Smart Citation

Hematological Disorders in Patients with Systemic Lupus Erythematosus

Bashal¹

2013

TORJ

View full text Add to dashboard Cite

This article is a review of different management strategies for the hematological manifestations of systemic lupus erythematosus (SLE), the strategies include immunosuppressive drugs, some noval therapies and B-cell depletion for refractory thrombocytopenia in patients with SLE and in antiphospholipid antibody syndrome associated with SLE. The researcher questions the validity of the current classic treatment modes and the article explores the relationships between SLE hematological manifestations and the level of morbidity and mortality burden and focuses on the pathophysiology, diagnostic approaches and management strategies of these manifestations.The researcher focuses on hematological abnormalities because they are the commonest among most manifestations in SLE seen in Anemia, leucopenias and thrombocytopenia. They commonly result from an immune mediated bone marrow failure, excessive peripheral cells destruction or certain drugs and infections. There is also an association between anti-phospholipid antibody syndrome (APS) and SLE referred to as secondary APS or SLE-APS. Furthermore, it was recently found that mycophenolatemofetil acts as corticosteroids and as cyclophosphamide sparing agent. Although there is no specific therapy for cytopenias in SLE, corticosteroids remain the mainstay in the treatment of these patients along with less used other conventional treatment options such as azathioprine, cyclophosphamide and human normal immunoglobulin. There are other novel therapies such as thrombopoietin receptor agonists in thrombocytopenia and the use of autologous hematopoitic stem cells transplantation in refractory SLE-APS that are under review. Some of these therapies include thrombopoietin receptor agonists in thrombocytopenia and the use of autologous hematopoitic stem cells transplantation in refractory SLE-APS.The study concludes that treatment of hematological abnormalities is challenging because the treatment itself can cause undue complications sometimes such as granulocytosis due to infection or the use of high doses of steroids and may occur during acute exacerbations of SLE. It is important to take these factors into consideration for disease therapy and management.Publication Abstract:This article is a review of different management strategies for the hematological manifestations of systemic lupus erythematosus (SLE). The strategies include immunosuppressive drugs, some novel therapies and B-cell depletion for refractory thrombocytopenia in patients with SLE and in anti-phospholipid antibody syndrome associated with SLE. The researcher questions the validity of the current classic treatment modes and the article explores the relationships between SLE hematological manifestations and the level of morbidity and mortality burden while it focuses on the pathophysiology, diagnostic approaches and management strategies. The study concludes that hematological abnormalities are the commonest among most manifestations in SLE, and that their treatment is challenging because the treatment itself can cau...

show abstract

“…Refractory APS, whether primary or secondary and catastrophic APS could be the appropriate targets for these therapies currently [61]. …”

Section: Managementmentioning

confidence: 99%

Section: Managementmentioning

confidence: 99%

Hematological Disorders in Patients with Systemic Lupus Erythematosus

Bashal¹

2013

TORJ

View full text Add to dashboard Cite

show abstract

“…Many patients, particularly those with primary HGP, will require no specific treatment, however, where attacks of rash and joint pains are frequent or debilitating successful therapy with colchicines, prednisolone, hydroxychloroquine, indomethacin, chlorambucil, rituximab and plasmapheresis have all been reported [4,5,7]. The antimalarial drug, hydroxychloroquine, appears to reverse platelet activation induced by human immunoglobulin aPL antibodies and decrease the thrombogenic properties of aPL antibodies and also appears to decrease aCL levels.…”

Section: Discussionmentioning

confidence: 99%

“…Contraception in these patients is best by copper or LNG IUCD. Estrogen-containing hormonal contraceptives may be used in stable, inactive SLE patients but are contraindicated in patients with positive aPL antibodies [7].…”

Section: Discussionmentioning

confidence: 99%

Hypergammaglobulinemic Purpura of Waldenstrom (HGPW) in Pregnancy: A Rare Case Report

Malik

Goyal

Ganju

et al. 2018

J Obstet Gynecol India

View full text Add to dashboard Cite

“…Treatment of APLS usually requires long‐term warfarin therapy with an international normalized ratio goal of 2–3 (Kearon et al , ). Patients with elevated antiphospholipid antibody levels and a history of arterial or venous thrombosis are at a higher risk of recurrence and are usually placed on lifelong warfarin therapy (Del Papa & Vaso, ). Finnazi () reported that the incidence of non‐Hodgkin lymphoma was significantly higher in patients with APLS than in the general population, suggesting that APLS may be a risk factor for the development of non‐Hodgkin lymphoma.…”

mentioning

confidence: 99%